Temozolomide (TMZ) is a chemotherapy drug used to treat high grade brain tumours known as gliomas, particularly anaplastic astrocytoma (Grade 3) and glioblastoma (Grade 4). It has been shown to improve how long some people live with these types of fast-growing tumour.
How is Temozolomide taken?
- TMZ is usually taken as a pill and a typical treatment would be radiotherapy for six to seven weeks alongside TMZ to be taken every day.
- During this phase, regular blood tests are taken to monitor your blood count and overall health. Based on these results, on a weekly basis, your oncologist will decide whether your treatment should continue, be postponed or discontinued.
- Four weeks after the end of radiotherapy you may enter the 'monotherapy phase' of TMZ treatment. This involves taking the drug for the first five days of a 28 day cycle. You may receive it for up to six such cycles (i.e. over a six month period).
- TMZ may also be prescribed when a tumour has not responded to other standard treatment, or when there is tumour recurrence.
How does Temozolomide work?
TMZ is a type of chemotherapy drug known as an alkylating agent. This means it binds to the DNA in cells and interferes specifically with cell growth and division.
Unlike many other drugs, it is able to pass across the blood-brain barrier (BBB). This is a membrane of cells that blocks potentially harmful substances in the blood from entering the brain. Most other chemotherapy drugs are unable to pass across this membrane and reach the brain.
Sometimes, for some people, TMZ doesn't work so well. This depends to a large extent on the concentration and form of the MGMT protein (which repairs DNA) in the tumour.
If you have further questions, need to clarify any of the information on this page, or want to find out more about research and clinical trials, please contact our team:
Support and Information Services
0808 800 0004 (free from landlines and mobiles)
Phone lines open Mon-Fri, 09:00-17:00
Research & Clinical Trials Information
You can also join our active online community on Facebook - find out more about our groups.